Faculty

Institution

Unit

Venue

Warren Fiskus

Assistant Professor of Leukemia

The University of Texas MD Anderson Cancer Center

Affiliations

Section Of Molecular Hematology And Therapy

Department Of Leukemia

Warren Fiskus is an Assistant Professor of Leukemia at The University of Texas MD Anderson Cancer Center. His research focuses on therapeutic targets and pharmacology in myeloid neoplasia, particularly acute myeloid leukemia (AML) and myeloproliferative neoplasms. He investigates epigenetic dependencies, including BET proteins and BRG1/BRM chromatin remodelers, to overcome menin inhibitor resistance and target MECOM-rearranged AML. His recent work also explores BCL-xL degraders for JAK2-mutated post-MPN AML and tasquinimod-based combinations for blastic-phase disease. His findings have been published in Blood, Leukemia, and HemaSphere.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Warren Fiskus

The University of Texas MD Anderson Cancer Center

Assistant Professor of Leukemia

You can click a keyword to filter the displayed items

cell biology leukemia pharmacology therapeutic targets oncogenes cancer research oncology cancer cells hematological malignancies myeloid neoplasia tumor biology hematology medicinal research immunology anti-cancer agents medicine molecular cancer novel therapies cancer treatment cancer biology enzyme inhibition cellular therapy cancer immunotherapy pharmacotherapy tumor targeting cell death cancer care molecular medicine clinical research therapeutic efficacy lymphoid neoplasia molecular cell biology cell regulation chromatin remodeling malignant blood disorders cancer discovery bone marrow transplantation cancer management aml cells drug targeting breast oncology cancer genetics receptor tyrosine kinases cancer genomics thrombosis cell therapy surgical oncology blood cells acute myeloid leukemia superior efficacy pre-clinical efficacy treatment effects remedial action drug targets hemostasis epigenetic therapy human aml cells endoplasmic reticulum stress preclinical efficacy mutant npm1 clinical chemistry apoptosis disease progression pediatric hematology tumor suppressors host specificity inhibitory activity chaperone function heat shock bet protein cellular immune responses pathogen characterization synergistic activity phase i-ii study myeloid malignancies anti-aml activity

Notable Scholarly Works

Notable Federal Grants

Collaborators

CORRECTION: Bet Inhibitor-Based Combinations Targeting Novel Dependencies in Mecom-Rearranged (R) Aml. Leukemia (2026)

hematological malignanciesnovel therapiescell biologyleukemiaoncogenestherapeutic targetsmyeloid neoplasia

Highly Effective Combination of Brg1/Brm Inhibitor With Bet Inhibitor or Decitabine for High‐Risk Mecom‐Rearranged Aml. HemaSphere (2026)

cancer researchnovel therapiesbrg1/brm inhibitorcell biologyleukemiaoncogenesimmunologypharmacologytherapeutic targetseffective combinationbet inhibitor

Overcoming Menin Inhibitor Resistance in Aml Cells With Combinations Including Bet Proteins and Dual Brg1/Brm Inhibitor. Blood (2026)

aml cellsbet proteinscell regulationcellular biologycell divisioncell biologycell signalingcancer cellsleukemiamolecular cell biologyoncogenestherapeutic targetsmolecular biologymenin inhibitor resistance

Abstract 451: Superior Preclinical Efficacy of Brg1/Brm Inhibitor Combined With Bet Inhibitor or Decitabine Against Mecom-Rearranged Aml. Cancer Research (2025)

cancer researchmolecular cancernovel therapiessuperior preclinical efficacycell biologyleukemiaoncogenespharmacologytherapeutic targetsexperimental medicineabstract 451pharmacotherapybet inhibitor

Abstract 6825: Novel Therapeutic Strategies Targeting Mecom Rearranged Amls Discovered by Unbiased Drug Screen. Cancer Research (2025)

abstract 6825novel therapiesunbiased drug screencell biologyleukemianovel therapeutic strategiesoncogenespharmacologydrug targetingtherapeutic targetsdrug discovery

A Pilot Study of Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With Runx1 Familial Platelet Disorder. Blood (2025)

hematologyplatelet antagonistmedicinehemostasishematopoietic functionhaematopoiesisthrombopoiesispharmacologypilot studythrombosislow-dose sirolimusblood platelet

Clinical Trial Protocol S1 From Phase I Results of Bromodomain and Extra-Terminal Inhibitor Plx51107 in Combination With Azacitidine in Patients With Relapsed/Refractory Myeloid Malignancies. (2025)

hematologymedicinemetronomic therapyrelapsed/refractory myeloid malignanciescancer researchoncologyhematological malignanciesmyeloid neoplasialeukemiaoncogenespharmacologyextra-terminal inhibitor plx51107therapeutic targetsmixed-phenotype acute leukemiapharmacotherapyclinical trials

CORRECTION: Targeting of Epigenetic Co-Dependencies Enhances Anti-Aml Efficacy of Menin Inhibitor in Aml With Mll1-R or Mutant Npm1. Blood Cancer Journal (2025)

epigeneticsmenin inhibitorcell biologyoncogenestherapeutic targetsmolecular biologymutant npm1

Efficacy of a Novel Bcl-XL Degrader, Dt2216, in Preclinical Models of Jak2 -Mutated Post-Mpn Aml. Blood (2025)

Zhe WangAnna SkwarskaGowri PoigaialwarSovira ChaudhryAlba Rodriguez-MeiraPinpin SuiEmmanuel OlivierYannan JiaVarun GuptaWarren FiskusCassandra L. RamageGuangrong ZhengAlexandra SchurerKira GritsmanEirini P PapapetrouKapil N BhallaDaohong ZhouAdam J. MeadRaajit K. RampalJeffrey W. TynerHussein A. AbbasNaveen PemmarajuQi Zhang TatarataMarina Y. Konopleva

hematologyimmunologynovel bcl-xl degraderpreclinical models

Ep31670, a Dual-Bet + P300 Inhibitor, Demonstrates Pre-Clinical Efficacy, Including in Combination With Jak Inhibition, in the Hmplw515L Adoptive Transfer Model of Myelofibrosis (Mf). Blood (2025)

hematologyhematological malignanciesmolecular cancernovel therapiesjak inhibitioncell biologyleukemiabone marrow transplantationoncogenespre-clinical efficacyimmunologypharmacologytherapeutic targetsexperimental medicinemedicinal researchmyeloid neoplasia

1
2
3
4
5
25
10 / page

Warren Fiskus

Assistant Professor of Leukemia

The University of Texas MD Anderson Cancer Center

Affiliations

Section Of Molecular Hematology And Therapy

Department Of Leukemia

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Warren Fiskus

The University of Texas MD Anderson Cancer Center

Assistant Professor of Leukemia

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

CORRECTION: Bet Inhibitor-Based Combinations Targeting Novel Dependencies in Mecom-Rearranged (R) Aml. Leukemia (2026)

hematological malignanciesnovel therapiescell biologyleukemiaoncogenestherapeutic targetsmyeloid neoplasia

Highly Effective Combination of Brg1/Brm Inhibitor With Bet Inhibitor or Decitabine for High‐Risk Mecom‐Rearranged Aml. HemaSphere (2026)

cancer researchnovel therapiesbrg1/brm inhibitorcell biologyleukemiaoncogenesimmunologypharmacologytherapeutic targetseffective combinationbet inhibitor

Overcoming Menin Inhibitor Resistance in Aml Cells With Combinations Including Bet Proteins and Dual Brg1/Brm Inhibitor. Blood (2026)

Abstract 451: Superior Preclinical Efficacy of Brg1/Brm Inhibitor Combined With Bet Inhibitor or Decitabine Against Mecom-Rearranged Aml. Cancer Research (2025)

cancer researchmolecular cancernovel therapiessuperior preclinical efficacycell biologyleukemiaoncogenespharmacologytherapeutic targetsexperimental medicineabstract 451pharmacotherapybet inhibitor

Abstract 6825: Novel Therapeutic Strategies Targeting Mecom Rearranged Amls Discovered by Unbiased Drug Screen. Cancer Research (2025)

abstract 6825novel therapiesunbiased drug screencell biologyleukemianovel therapeutic strategiesoncogenespharmacologydrug targetingtherapeutic targetsdrug discovery

A Pilot Study of Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With Runx1 Familial Platelet Disorder. Blood (2025)

hematologyplatelet antagonistmedicinehemostasishematopoietic functionhaematopoiesisthrombopoiesispharmacologypilot studythrombosislow-dose sirolimusblood platelet

Clinical Trial Protocol S1 From Phase I Results of Bromodomain and Extra-Terminal Inhibitor Plx51107 in Combination With Azacitidine in Patients With Relapsed/Refractory Myeloid Malignancies. (2025)

CORRECTION: Targeting of Epigenetic Co-Dependencies Enhances Anti-Aml Efficacy of Menin Inhibitor in Aml With Mll1-R or Mutant Npm1. Blood Cancer Journal (2025)

epigeneticsmenin inhibitorcell biologyoncogenestherapeutic targetsmolecular biologymutant npm1

Efficacy of a Novel Bcl-XL Degrader, Dt2216, in Preclinical Models of Jak2 -Mutated Post-Mpn Aml. Blood (2025)

hematologyimmunologynovel bcl-xl degraderpreclinical models

Ep31670, a Dual-Bet + P300 Inhibitor, Demonstrates Pre-Clinical Efficacy, Including in Combination With Jak Inhibition, in the Hmplw515L Adoptive Transfer Model of Myelofibrosis (Mf). Blood (2025)

1
2
3
4
5
25
10 / page